➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Harvard Business School
Moodys
Dow
Colorcon

Last Updated: May 12, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TIVOZANIB HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Tivozanib Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00502307 A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma Completed AVEO Pharmaceuticals, Inc. Phase 2 2007-10-01 This phase 2 trial is evaluating the antineoplastic activity of tivozanib (AV-951) in treating patients with recurrent or metastatic renal cell cancer. Tivozanib (AV-951) is a VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking blood flow to the tumor.
NCT00563147 A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma Completed AVEO Pharmaceuticals, Inc. Phase 1 2007-11-01 The purpose of this study is to test the safety and tolerability of tivozanib (AV-951) and Torisel™ given in combination for renal cell cancer. The study will also assess the effects of the combination of tivozanib (AV-951) and Torisel™ on the tumor. Tivozanib (AV-951) is a VEGF-receptor tyrosine kinase inhibitor, and may stop the growth of tumor cells by blocking blood flow to the tumor. Temsirolimus is an mTOR inhibitor which is approved for the treatment of advanced renal cell carcinoma.
NCT00660153 Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers Completed AVEO Pharmaceuticals, Inc. Phase 1 2008-06-01 The FOLFOX6 regimen is a standard chemotherapy regimen for the treatment of patients with colorectal cancer and other gastrointestinal cancers. Tivozanib (AV-951) is a targeted anti-angiogenesis agent that has demonstrated acceptable tolerability in a phase I clinical trial. This study is designed to test the hypothesis that tivozanib (AV-951) can be combined with standard FOLFOX6 chemotherapy for the treatment of patients with colorectal and other gastrointestinal cancers. The purpose of this study is to determine the maximum dose of tivozanib (AV-951) that can be safely combined with FOLFOX6 chemotherapy, and to evaluate the safety profile, tolerability, and pharmacokinetics of this combination.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tivozanib Hydrochloride

Condition Name

Condition Name for Tivozanib Hydrochloride
Intervention Trials
Carcinoma, Renal Cell 3
Renal Cell Carcinoma 3
Advanced Solid Tumors 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tivozanib Hydrochloride
Intervention Trials
Carcinoma 11
Carcinoma, Renal Cell 10
Colorectal Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tivozanib Hydrochloride

Trials by Country

Trials by Country for Tivozanib Hydrochloride
Location Trials
United States 146
India 19
Canada 18
France 14
United Kingdom 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tivozanib Hydrochloride
Location Trials
Florida 11
Massachusetts 10
Texas 9
New York 9
California 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tivozanib Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Tivozanib Hydrochloride
Clinical Trial Phase Trials
Phase 3 3
Phase 2 12
Phase 1/Phase 2 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tivozanib Hydrochloride
Clinical Trial Phase Trials
Completed 17
Active, not recruiting 4
Terminated 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tivozanib Hydrochloride

Sponsor Name

Sponsor Name for Tivozanib Hydrochloride
Sponsor Trials
AVEO Pharmaceuticals, Inc. 26
National Comprehensive Cancer Network 5
National Cancer Institute (NCI) 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tivozanib Hydrochloride
Sponsor Trials
Industry 30
Other 15
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Colorcon
Harvard Business School
Boehringer Ingelheim
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.